Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
- Previous Close
84.70 - Open
84.15 - Bid 85.20 x --
- Ask 85.25 x --
- Day's Range
82.50 - 85.30 - 52 Week Range
37.96 - 86.90 - Volume
79,509 - Avg. Volume
82,380 - Market Cap (intraday)
4.356B - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
26.56 - EPS (TTM)
3.20 - Earnings Date May 8, 2024
- Forward Dividend & Yield 1.29 (1.52%)
- Ex-Dividend Date Jul 3, 2023
- 1y Target Est
68.09
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
www.rovi.esRecent News: ROVI.MC
Performance Overview: ROVI.MC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ROVI.MC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ROVI.MC
Valuation Measures
Market Cap
4.35B
Enterprise Value
4.39B
Trailing P/E
26.56
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.45
Price/Book (mrq)
8.07
Enterprise Value/Revenue
5.30
Enterprise Value/EBITDA
17.90
Financial Highlights
Profitability and Income Statement
Profit Margin
20.53%
Return on Assets (ttm)
16.34%
Return on Equity (ttm)
31.98%
Revenue (ttm)
829.51M
Net Income Avi to Common (ttm)
170.34M
Diluted EPS (ttm)
3.20
Balance Sheet and Cash Flow
Total Cash (mrq)
25.32M
Total Debt/Equity (mrq)
12.04%
Levered Free Cash Flow (ttm)
25.34M
Research Analysis: ROVI.MC
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: ROVI.MC
ROVI.MC does not have Company Insights